Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Autor: Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Rok vydání: 2020
Předmět:
Oncology
Cancer Research
Receptor
ErbB-2
Biopsy
medicine.medical_treatment
Gene Expression
Disease
Metastasis
0302 clinical medicine
Breast cancer
Breast
Molecular Targeted Therapy
030212 general & internal medicine
HER2 negative
General Medicine
Middle Aged
Metastatic breast cancer
Immunohistochemistry
Receptors
Estrogen
Hormone receptor
030220 oncology & carcinogenesis
Practice Guidelines as Topic
Hormonal therapy
Female
Menopause
Receptors
Progesterone
Research Article
medicine.medical_specialty
Consensus
Neoplasms
Hormone-Dependent
Antineoplastic Agents
Hormonal
Hormonal resistance
Clinical Decision-Making
Breast Neoplasms
Luminal
Càncer de mama
03 medical and health sciences
Therapeutic approach
Metàstasi
Internal medicine
Biomarkers
Tumor
medicine
Humans
Hormone therapy
Aged
business.industry
Ovary
medicine.disease
Ki-67 Antigen
Drug Resistance
Neoplasm
Hormonal receptor
Neoplasm Recurrence
Local
business
Hormonoteràpia
Zdroj: Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Popis: PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making.MethodsThis consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer.ResultsA Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making.ConclusionWe have developed a consensus document with recommendations on the treatment of patients with HER2-negative luminal MBC that will help to improve therapeutic benefits.
Databáze: OpenAIRE
Externí odkaz: